GLUE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
54.4M
+506.2%
9.0M
+113.0%
4.2M
+51.4%
2.8M
-78.2%
12.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
54.4M
+506.2%
9.0M
+113.0%
4.2M
+51.4%
2.8M
-78.2%
12.8M
Operating Expenses
56.3M
-3.1%
58.1M
+7.1%
54.2M
+3.3%
52.5M
+14.8%
45.7M
R&D
45.4M
-5.4%
48.0M
+8.8%
44.1M
+5.0%
42.0M
+14.5%
36.7M
SG&A
10.9M
+8.0%
10.1M
-0.4%
10.2M
-3.3%
10.5M
+16.0%
9.1M
Operating Income
-1939000
+96.1%
-49130000
+1.8%
-50034000
-0.6%
-49715000
-50.8%
-32975000
EBITDA
205.0K
+100.4%
-47216000
+1.6%
-48005000
-0.8%
-47627000
-54.2%
-30880000
Net Income
3.1M
+107.1%
-43397000
+2.5%
-44503000
+3.5%
-46135000
-70.4%
-27081000
EPS (Basic)
$0.03
+107.0%
$-0.43
+4.4%
$-0.45
+16.7%
$-0.54
-63.6%
$-0.33
EPS (Diluted)
$0.03
+107.0%
$-0.43
+4.4%
$-0.45
+16.7%
$-0.54
-63.6%
$-0.33
Shares (Diluted)
108.6M
+7.0%
101.5M
+1.6%
99.9M
+17.9%
84.7M
+2.8%
82.4M
Monte Rosa Therapeutics (GLUE) — Financials